Results 121 to 130 of about 13,220 (219)

AmpC β-lactamase induction by avibactam and relebactam [PDF]

, 2017
Background: Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.
Jamrozy, Dorota, Livermore, David M, Mushtaq, Shazad, Nichols, Wright W, Woodford, Neil, Young, Katherine   +5 more
core   +1 more source

Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam

Journal of Family Medicine and Primary Care
ABSTRACT Background: Multidrug resistant (MDR) Gram negative organisms are becoming increasingly common. Carbapenem resistant Enterobacterales (CRE) pose a major threat and necessitate the development of new antibiotics.
Sunali, Mithilesh Kumar Jha, Mukesh Kumar, Maneesh Kumar, Nishant Ranjan   +4 more
openaire   +3 more sources

Интраабдоминальная инфекция в свете последних международных рекомендаций и ее роль в развитии септической энцефалопатии [PDF]

, 2018
Цель данных рекомендаций: представить международную позицию, основанную на доказательствах, по вопросам тактики ведения интраабдоминальных инфекций и влияние интраабдоминальных инфекций на развитие септической энцефалопатии.
Лисничая, В.Н., Мальцева, Л.А., Мосенцев, Н.Ф.   +2 more
core  

Suboptimal ceftazidime-avibactam exposure drives sequential blaKPC mutations and intra-host coexistence of Klebsiella pneumoniae harboring distinct variants leading to persistent infection

Microbiology Spectrum
KPC-producing Klebsiella pneumoniae infections are a rising global health threat. The factors driving blaKPC mutations during treatment and their contribution to infection persistence remain unclear.
Feng Yang, Weiwei Yang, Jinghao Zhang, Chengkang Tang, Li Ding, Siquan Shen, Yanhao Zhou, Hongyu Zhao, Jiaojiao Zhou, Fupin Hu   +9 more
doaj   +1 more source

Diverse evolutionary trajectories of Klebsiella pneumoniae carbapenemase: unraveling the impact of amino acid substitutions on β-lactam susceptibility and the role of avibactam in driving resistance

mSystems
Klebsiella pneumoniae carbapenemases (KPCs) have evolved into over 245 distinct variants, with over one-third of variants exhibiting reduced susceptibility to ceftazidime-avibactam, while the underlying selection mechanisms remain elusive.
Jie Wei, Jinyu Huang, Chunhong Zou, Shimei Shen, Barry N. Kreiswirth, Ailong Huang, Shifeng Huang, Liang Chen, Deqiang Wang, Siqiang Niu   +9 more
doaj   +1 more source

The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020

Eurosurveillance
Background Ceftazidime/avibactam, launched in the United Kingdom (UK) in March 2017, is an antibiotic against multidrug-resistant Gram-negative pathogens.
Berit Muller-Pebody
doaj   +1 more source

Ceftazidime/avibactam for specified infections [PDF]

Australian Prescriber, 2020
openaire   +2 more sources

Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia

Journal of Infection and Public Health
Background: Ceftazidime-avibactam (CZA) is the preferred treatment for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). This study aimed to investigate the prognostic factors of 28-day mortality and 14-day clinical failure in patients treated with CZA for CZA-susceptible CRKP bacteremia.
Yi-Tsung Lin, Shih-Neng Lin, Chien Chuang, Szu-Yu Liu, Yu-Chien Ho, Chih-Han Juan, Hsiang-Ling Ho, Sheng-Hua Chou   +7 more
openaire   +2 more sources

Effectiveness of Ceftazidime/Avibactam treatment for infections caused by Klebsiella pneumoniae Carbapenemase (KPC), a 30-day mortality perspective. Comparison of results with control groups treated with other antibiotics

Journal of Education, Health and Sport
Introduction: Infections caused by Klebsiella pneumoniae carbapenemase (KPC) pose a significant clinical challenge due to increasing antibiotic resistance.
Patrycja Paschke, Igor Miczek, Maria Sambura, Sara Rosołowska-Żak, Julia Pałuchowska, Anna Szymkowicz   +5 more
doaj   +1 more source

Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration

Pharmacology Research & Perspectives
Ceftazidime–avibactam is a novel cephalosporin/beta‐lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in ...
Michael Thy, Alexandre Debs, Gabrielle Lui, Leo Froelicher‐Bournaud, Jean‐Marc Tréluyer, Mehdi Oualha   +5 more
doaj   +1 more source